Form 4: MAIA Biotechnology Director Acquires Stock Options

Steven M. Chaouki, a director of MAIA Biotechnology, Inc., acquired 20,667 stock options on April 4, 2025, which vest immediately.

Summary

• On April 4, 2025, Steven M. Chaouki, a director of MAIA Biotechnology, Inc., acquired 20,667 stock options.
• The stock options were granted pursuant to the company's 2021 Equity Incentive Plan.
• The options vest 100% on the grant date and are exercisable immediately.
• Each option allows the holder to buy one share of common stock at an exercise price of $1.50.
• The options expire on April 4, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director generally indicates confidence in the company, but it's a routine transaction.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This provides transparency to the market.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

stock options, director, MAIA Biotechnology, equity incentive plan, beneficial ownership, Form 4